Business, energy, technology, markets and global industry news from Business News Today

Akeso Inc.

PharmaDeviceNews Akeso Inc.
Summit Therapeutics enters a pivotal phase for ivonescimab as the oncology developer deploys its $690.7 million cash position toward an upcoming FDA decision, HARMONi-3 data and an expanding late-stage lung cancer programme. Representative image.
Pharma & Biotech

Summit Therapeutics has $690.7m, but one November FDA decision now towers over everything

Summit Therapeutics ends Q2 with $690.7m as ivonescimab approaches an FDA decision and pivotal HARMONi-3 data in late 2026.

Read More
Summit Therapeutics’ updated HARMONi analysis strengthens the ivonescimab survival trend in Western and Asian lung cancer patients ahead of the FDA decision. Representative image.
Pharma & Biotech

Summit Therapeutics nears FDA decision with stronger ivonescimab survival signal

Ivonescimab’s updated HARMONi survival trend strengthens before the FDA’s November decision, but key statistical details remain undisclosed.

Read More
Representative image: A clinician reviews lung cancer imaging as ivonescimab survival data from the HARMONi-6 study raise fresh questions about the future of first-line squamous non-small cell lung cancer treatment.
Pharma & Biotech

Can Summit and Akeso turn ivonescimab into a global lung cancer challenger?

Ivonescimab showed an overall survival benefit in HARMONi-6. Read how the data could reshape first-line squamous NSCLC treatment.

Read More